Literature DB >> 25073960

Modulation of both activator protein-1 and nuclear factor-kappa B signal transduction of human T cells by amiodarone.

Shu-Meng Cheng1, Wei-Hsiang Lin1, Chin-Sheng Lin1, Ling-Jun Ho2, Tsung-Neng Tsai1, Chun-Hsien Wu1, Jenn-Haung Lai3, Shih-Ping Yang4.   

Abstract

Amiodarone, a common and effective antiarrhythmic drug, has been reported to have anti-inflammatory effects such as reducing the activation and movement of neutrophils. However, its effects on human T cells remain unclear. The aim of this study was to elucidate the effects and possible underlying mechanisms of amiodarone on human T cells. We isolated human primary T cells from the peripheral blood of healthy volunteers and performed enzyme-linked immunosorbent assay (ELISA), flow cytometry, electrophoretic mobility shift assay, luciferase assay, and Western blotting to evaluate the modulatory effects of amiodarone on human T cells. We found that amiodarone dose dependently inhibited the production of cytokines, including interleukin-2 (IL-2), IL-4, tumor necrosis factor-alpha, and interferon-gamma in activated human T cells. By flow cytometry, we demonstrated that amiodarone suppressed the expression of IL-2 receptor-alpha (CD25) and CD69, the cell surface markers of activated T cells. Moreover, molecular investigations revealed that amiodarone down-regulated activator protein-1 (AP-1) and nuclear factor kappa-B (NF-κB) DNA-binding activities in activated human T cells and also inhibited DNA binding and transcriptional activities of both AP-1 and NF-κB in Jurkat cells. Finally, by Western blotting, we showed that amiodarone reduced the activation of c-Jun NH(2)-terminal protein kinase and P38 mitogen-activated protein kinase, and suppressed stimuli-induced I-kappa B-alpha degradation in activated human T cells. Through regulation of AP-1 and NF-κB signaling, amiodarone inhibits cytokine production and T cell activation. These results show the pleiotropic effects of amiodarone on human T cells and suggest its therapeutic potential in inflammation-related cardiovascular disorders.
© 2014 by the Society for Experimental Biology and Medicine.

Entities:  

Keywords:  Amiodarone; T cells; activator protein-1; cytokine; nuclear factor kappa-B

Mesh:

Substances:

Year:  2014        PMID: 25073960      PMCID: PMC4935190          DOI: 10.1177/1535370214544263

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  60 in total

Review 1.  Signal transduction pathways: targets for chemoprevention of skin cancer.

Authors:  A M Bode; Z Dong
Journal:  Lancet Oncol       Date:  2000-11       Impact factor: 41.316

2.  Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes.

Authors:  S S Rathore; A K Berger; K P Weinfurt; K A Schulman; W J Oetgen; B J Gersh; A J Solomon
Journal:  Circulation       Date:  2000-03-07       Impact factor: 29.690

3.  Modulation of human T cells signaling transduction by lovastatin.

Authors:  Shu-Meng Cheng; Jenn-Haung Lai; Shih-Ping Yang; Tien-Ping Tsao; Ling-Jun Ho; Jun-Ting Liou; Cheng-Chung Cheng
Journal:  Int J Cardiol       Date:  2008-11-28       Impact factor: 4.164

4.  The essential role of MEKK3 in TNF-induced NF-kappaB activation.

Authors:  J Yang; Y Lin; Z Guo; J Cheng; J Huang; L Deng; W Liao; Z Chen; Z Liu; B Su
Journal:  Nat Immunol       Date:  2001-07       Impact factor: 25.606

5.  Improving survival for patients with atrial fibrillation and advanced heart failure.

Authors:  W G Stevenson; L W Stevenson; H R Middlekauff; G C Fonarow; M A Hamilton; M A Woo; L A Saxon; P D Natterson; A Steimle; J A Walden; J H Tillisch
Journal:  J Am Coll Cardiol       Date:  1996-11-15       Impact factor: 24.094

6.  Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators.

Authors:  J A Cairns; S J Connolly; R Roberts; M Gent
Journal:  Lancet       Date:  1997-03-08       Impact factor: 79.321

Review 7.  Lipid-altering therapy and atrial fibrillation.

Authors:  Justin M Bachmann; Maulik Majmudar; Christine Tompkins; Roger S Blumenthal; Joseph E Marine
Journal:  Cardiol Rev       Date:  2008 Jul-Aug       Impact factor: 2.644

8.  Rising rates of hospital admissions for atrial fibrillation.

Authors:  Jens Friberg; Pernille Buch; Henrik Scharling; Niels Gadsbphioll; Gorm B Jensen
Journal:  Epidemiology       Date:  2003-11       Impact factor: 4.822

9.  Amiodarone: pharmacology and antiarrhythmic and adverse effects.

Authors:  G V Naccarelli; R L Rinkenberger; A H Dougherty; R A Giebel
Journal:  Pharmacotherapy       Date:  1985 Nov-Dec       Impact factor: 4.705

10.  Amiodarone causes decreased cell-mediated immune responses and inhibits the phospholipase C signaling pathway.

Authors:  B D Wilson; C E Clarkson; M L Lippmann
Journal:  Lung       Date:  1993       Impact factor: 2.584

View more
  2 in total

1.  Differential cytokine profiling in Chagasic patients according to their arrhythmogenic-status.

Authors:  Héctor Rodríguez-Angulo; Juan Marques; Ivan Mendoza; Marco Villegas; Alfredo Mijares; Núria Gironès; Manuel Fresno
Journal:  BMC Infect Dis       Date:  2017-03-21       Impact factor: 3.090

2.  Amiodarone promotes cancer cell death through elevated truncated SRSF3 and downregulation of miR-224.

Authors:  Yung-Lung Chang; Shu-Ting Liu; Yi-Wen Wang; Wei-Shiang Lin; Shih-Ming Huang
Journal:  Oncotarget       Date:  2018-02-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.